Effect of a 28-d treatment with L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure and body composition in obese men

Larsen, Thomas M, Toubro, Søren, van Baak, Marleen A, Gottesdiener, Keith M, Larson, Patrick, Saris, Wim HM, Astrup, Arne·2002·The American Journal of Clinical Nutrition
DOI 10.1093/ajcn/76.4.780

Cited by (184)

Items 101–184 of 184

  1. Sortilin-mediated translocation of mitochondrial ACSL1 impairs adipocyte thermogenesis and energy expenditure in male mice
    Min Yang, Jing Ge, Yulian Liu, Huan-Yu Wang, Zhihan Wang, Danpei Li, Rui He, Yuyu Xie, Hongyan Deng, Xuemin Peng et al. · 2024 · Nature Communications
  2. The Adipose Organ
    Saverio Cinti · 2007 · Humana Press eBooks
  3. Translational Pharmacology and Physiology of Brown Adipose Tissue in Human Disease and Treatment
    Christopher J. Larson · 2018 · Handbook of experimental pharmacology
  4. Therapeutic prospects of metabolically active brown adipose tissue in humans
    Matthias Johannes Betz · 2011 · Frontiers in Endocrinology
  5. From Obesity to Diabetes: The Role of the Adipose Organ
    Georgia Colleluori, Jessica Perugini, Antonio Giordano, Saverio Cinti · 2022 · Handbook of experimental pharmacology
  6. AHNAK deficiency promotes browning and lipolysis in mice via increased responsiveness to β-adrenergic signalling
    Jae Hoon Shin, Seo Hyun Lee, Yo Na Kim, Il Yong Kim, Youn Ju Kim, Dong Soo Kyeong, Hee Jung Lim, Soo Young Cho, Junhee Choi, Young Jin Wi et al. · 2016 · Scientific Reports
  7. Hormonal factors in the control of the browning of white adipose tissue
    Jiamiao Hu, Mark Christian · 2017 · Hormone Molecular Biology and Clinical Investigation
  8. Thermic effect of a meal and appetite in adults: an individual participant data meta-analysis of meal-test trials
    Anne-Marie Ravn, Nikolaj Ture Gregersen, Robin Christensen, Lone Graasbøl Rasmussen, Ole Holm Hels, Anita Belza, Anne Raben, Thomas Meinert Larsen, Søren Toubro, Arne Vernon Astrup · 2013 · Food & Nutrition Research
  9. Housing mice near vs. below thermoneutrality affects drug-induced weight loss but does not improve prediction of efficacy in humans
    Julie Mie Jacobsen, Natalia Petersen, Lola Torz, Marina Kjærgaard Gerstenberg, Kent Pedersen, Søren Østergaard, Birgitte Schjellerup Wulff, Birgitte Andersen, Kirsten Raun, Berit Østergaard Christoffersen et al. · 2024 · Cell Reports
  10. Identification of a Nonbasic Melanin Hormone Receptor 1 Antagonist as an Antiobesity Clinical Candidate
    William N. Washburn, Mark C. Manfredi, Pratik V. Devasthale, Guohua Zhao, Saleem Ahmad, Andrés S. Hernández, Jeffrey A. Robl, Wei Wang, James Mignone, Zhenghua Wang et al. · 2014 · Journal of Medicinal Chemistry
  11. Diabetogenic effects of cardioprotective drugs
    David S.H. Bell, Edison Gonçalves · 2020 · Diabetes Obesity and Metabolism
  12. Stimulation of the ADRB3 Adrenergic Receptor Induces Relaxation of Human Placental Arteries: Influence of Preeclampsia1
    Céline Rouget, Olivier Barthez, Françoise Goirand, M Leroy, Michelle Breuiller-Fouché, Zo Rakotoniaina, Pascal Guérard, Esteban Jesús Morcillo, Charles Advenier, Paul Sagot et al. · 2005 · Biology of Reproduction
  13. Identification of key candidate genes and molecular pathways in white fat browning: an anti-obesity drug discovery based on computational biology
    Yuyan Pan, Jiaqi Liu, Fazhi Qi · 2019 · Human Genomics
  14. HDAC11 inhibition triggers bimodal thermogenic pathways to circumvent adipocyte catecholamine resistance
    Emma Louise Robinson, Rushita Adhikari Bagchi, Jennifer L. Major, Bryan C. Bergman, Jennifer L. Matsuda, Timothy A. McKinsey · 2023 · Journal of Clinical Investigation
  15. Implications of thermogenic adipose tissues for metabolic health
    Christian Schlein, Jöerg Heeren · 2016 · Best Practice & Research Clinical Endocrinology & Metabolism
  16. Potent and selective, sulfamide-based human β3-adrenergic receptor agonists
    Robert L. Dow, Ernest S. Paight, Steven R. Schneider, John R. Hadcock, Diane M. Hargrove, Kelly A. Martin, Tristan S. Maurer, Nancy A. Nardone, David A. Tess, Paul A DaSilva-Jardine · 2004 · Bioorganic & Medicinal Chemistry Letters
  17. Interventions associated with brown adipose tissue activation and the impact on energy expenditure and weight loss: A systematic review
    Perez, Luis C., Perez, Laura T., Nene, Yash, Umpierrez, Guillermo E., Davis, Georgia M., Pasquel, Francisco J. · 2022 · Frontiers in Endocrinology
  18. Distribution and quantification of β-3 adrenergic receptor in tissues of sheep
    J.L. Wu, Wei-yi LIU, J.H. Liu, Liying Qiao, Yanan Yuan · 2010 · animal
  19. Integrated control of brown adipose tissue.
    Emanuele Marzetti, Emanuela D’Angelo, Giulia Savera, Christiaan Leeuwenburgh, Riccardo Calvani · 2016 · PubMed
  20. Adipose targets for obesity drug development
    Olivier Boss, Nils C. H. Bergenhem · 2006 · Expert Opinion on Therapeutic Targets
  21. Is the β3-Adrenoceptor a Valid Target for the Treatment of Obesity and/or Type 2 Diabetes?
    Haneen S. Dwaib, Martin Christian Michel · 2023 · Biomolecules
  22. Physiological and metabolic functions of the β3-adrenergic receptor and an approach to therapeutic achievements
    Saptadip Samanta, Debasis Bagchi, Manashi Bagchi · 2024 · Journal of Physiology and Biochemistry
  23. Endocrine and autocrine/paracrine modulators of brown adipose tissue mass and activity as novel therapeutic strategies against obesity and type 2 diabetes
    Marcel Scheideler, Stephan Herzig, Anastasia Georgiadi · 2017 · Hormone Molecular Biology and Clinical Investigation
  24. Alternative Polyadenylation and Differential Regulation of Ucp1: Implications for Brown Adipose Tissue Thermogenesis Across Species
    Wen-Hsin Lu, Yao‐Ming Chang, Yi‐Shuian Huang · 2021 · Frontiers in Pediatrics
  25. The involvement of the adrenergic nervous system in activating human brown adipose tissue and browning
    Yolanda Oliveira Pinto, William T. Festuccia, Juliana Magdalon · 2022 · HORMONES
  26. Mirabegron-induced brown fat activation does not exacerbate atherosclerosis in mice with a functional hepatic ApoE-LDLR pathway
    Zhixiong Ying, Robin van Eenige, Rosa Beerepoot, Mariëtte R. Boon, Niels Kloosterhuis, Bart van de Sluis, Alexander Bartelt, Patrick C.N. Rensen, Sander Kooijman · 2022 · Pharmacological Research
  27. Modulation of adipose tissue thermogenesis as a method for increasing energy expenditure
    M. F. Sammons, David A. Price · 2013 · Bioorganic & Medicinal Chemistry Letters
  28. Topical menthol, a pharmacological cold mimic, induces cold sensitivity, adaptive thermogenesis and brown adipose tissue activation in mice
    Polina Sankina, Roshan Lal, Pragyanshu Khare, Stephan von Hörsten, Lars Fester, Vaishali Aggarwal, Katharina Zimmermann, Mahendra Bishnoi · 2024 · Diabetes Obesity and Metabolism
  29. Activating Connexin43 gap junctions primes adipose tissue for therapeutic intervention
    Yi Zhu, Na Li, Mingyang Huang, Xi Chen, Yu An, Jianping Li, Shangang Zhao, Jan‐Bernd Funcke, Jianhong Cao, Zhenyan He et al. · 2022 · Acta Pharmaceutica Sinica B
  30. Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonists
    Gregori J. Morriello, Harvey R. Wendt, Alka Bansal, Jerry Di Salvo, Scott D. Feighner, Jiafang He, Amanda L. Hurley, Donna L. Hreniuk, Gino Salituro, Marat Vijay Reddy et al. · 2010 · Bioorganic & Medicinal Chemistry Letters
  31. Exercise Alleviates Aging of Adipose Tissue through Adipokine Regulation
    Dandan Jia, Huijie Zhang, Tiemin Liu, Ru Wang · 2024 · Metabolites
  32. Sympathetic Nervous System Signaling in Heart Failure and Cardiac Aging
    Gaetano Santulli · 2015 · Springer eBooks
  33. DNA‐mediated UCP1 overexpression in adipose tissue: A promising anti‐obesity gene therapy
    Zewei Zhao, Longyun Hu, Bigui Song, Qian Wu, Jiejing Lin, Qingqing Liu, Siqi Liu, Jin Li, Molin Wang, Jin Li et al. · 2025 · Clinical and Translational Medicine
  34. The β-adrenergic antagonist propranolol partly abolishes thermogenic response to bioactive food ingredients
    Anita Belza, Maj-Britt Gille, Sarah Schultz John, Jens Kondrup · 2009 · Metabolism
  35. Molecular pharmacology of GPCRs
    Christopher J. Langmead, Roger J. Summers · 2018 · British Journal of Pharmacology
  36. Single-nuclei RNA Profiling Reveals Disruption of Adipokine and Inflammatory Signaling in Adipose Tissue of Burn Patients
    Carly M. Knuth, Zachary Ricciuti, Dalia Barayan, Sarah Rehou, Abdikarim Abdullahi, Lauar de Brito Monteiro, Marc G. Jeschke · 2023 · Annals of Surgery
  37. Pharmacological Treatment of the Overweight Patient
    2007 · Humana Press eBooks
  38. Potent benzimidazolone based human β3-adrenergic receptor agonists
    Don R. Finley, Michael G. Bell, Anthony G. Borel, William E. Bloomquist, Marlene L. Cohen, Mark L. Heiman, Aidas Kriauciunas, Donald P. Matthews, Tania Miles, David A. Neel et al. · 2006 · Bioorganic & Medicinal Chemistry Letters
  39. From Beneath the Skin to the Airway Wall: Understanding the Pathological Role of Adipose Tissue in Comorbid Asthma‐Obesity
    Carolyn Wang, Peter B. Noble, John Elliot, Alan L. James, Kimberley C. W. Wang · 2023 · Comprehensive physiology
  40. Reduced response to an estrous induction program in postpartum beef cows treated with zilpaterol and gaining body weight
    Adrian Guzmán, Everardo González-Padilla, Pedro Garces-Yepez, Jorge Víctor Rosete Fernández, René Carlos Calderón Robles, Clara Murcia, Carlos G. Gutiérrez · 2012 · Animal Reproduction Science
  41. Combination of a Beta Adrenoceptor Modulator and a Norepinephrine-Serotonin Uptake Inhibitor for the Treatment of Obesity
    Cynthia D. Jesudason, James E. Baker, Robert D. Bryant, Jack W. Fisher, Libbey S. O’Farrell, Gregory A. Gaich, Minxia Michelle He, Steven D. Kahl, Aidas Kriauciunas, Mark L. Heiman et al. · 2011 · ACS Medicinal Chemistry Letters
  42. The Adrenergic System in Cardiovascular Metabolism and Aging
    Gaetano Santulli · 2015 · Springer eBooks
  43. Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
    María Luisa Isidro, Fernando Cordido · 2010 · Pharmaceuticals
  44. Angiotensin II type 2 receptor as a novel activator of brown adipose tissue in obesity
    Fabiola Álvarez-Gallego, Raquel González‐Blázquez, Marta Gil‐Ortega, Beatriz Somoza, María Calderón‐Domínguez, Javier Moratinos, Virginia García‐García, Paloma Fernández, Daniel González‐Moreno, Marta Viana et al. · 2023 · BioFactors
  45. Effect of the β3 adrenoceptor agonist CL 316243 on hypothalamic 5-HT synthesis and suppression of REM sleep in the rat
    Rachel K. Conley, J. Li, M. Ivarsson, Peter H. Hutson · 2006 · Journal of Psychopharmacology
  46. Longitudinal trends and subgroup analysis in publication patterns for preclinical data of newly approved drugs
    Ursula Köster, Ingo J. A. Nolte, Martin Christian Michel · 2015 · Naunyn-Schmiedeberg s Archives of Pharmacology
  47. Plasticity of the Adipose Organ
    Saverio Cinti · 2010 · Wiley eBooks
  48. Weight-Loss Drugs
    George A. Bray, Frank L. Greenway · 2007 · Humana Press eBooks
  49. Inducible UCP1 silencing: A lentiviral RNA-interference approach to quantify the contribution of beige fat to energy homeostasis
    Nicole Wen Mun Khor, Michael M. Swarbrick, Jenny Elizabeth Gunton · 2019 · PLoS ONE
  50. Targeting Thermogenesis in the Development of Antiobesity Drugs
    Ruth McPherson, Frédérique Tesson, Robert Dent, Mary‐Ellen Harper · 2004 · CRC Press eBooks
  51. Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies
    Sahar Soliman, Rebecca Andrews‐Dickert, Petra Ročić, Mihail I. Mitov · 2025 · Pharmaceuticals
  52. Targeting Thermogenesis in the Development of Antiobesity Drugs
    Ruth Mcpherson, Frédérique Tesson, Robert Dent, Mary-Ellen Harper · 2004 · CRC Press eBooks
  53. Brown Adipose Tissue: A New Target for Antiobesity Therapy
    Anna Meiliana, Andi Wijaya · 2010 · The Indonesian Biomedical Journal
  54. β 3 -AR Agonists for the Treatment of Overactive Bladder
    Scott D. Edmondson · 2016 · Elsevier eBooks
  55. Influencing energy expenditure and substrate utilisation
    John C. Clapham, Jonathan R.S. Arch · 2008 · Birkhäuser Basel eBooks
  56. Drugs with Thermogenic Properties
    Arne Vernon Astrup, Søren Toubro · 2008 · CRC Press eBooks
  57. Evaluating the teratogenicity of the selective ß3-adrenoceptor agonist, CL 316.243 hydrate by employing FETAX (frog embryo teratogenesis assay)
    Ayper Boğa, Yaşar Sertdemır, Ayşe Doğan · 2016 · Drug and Chemical Toxicology
  58. A Status of Drugs on the Horizon for Obesity and the Metabolic Syndrome—a Comprehensive Review 2005
    Frank L. Greenway, George A. Bray · 2007 · Springer eBooks
  59. Zukunftsperspektiven der medikamentösen Therapie bei Adipositas
    Birgit Pichler, Bernhard H. Ludvik · 2003 · Journal für Kardiologie (Krause & Pachernegg GmbH)
  60. Browning of Adipose Organ
    Saverio Cinti · 2014 · Springer eBooks
  61. Strategies to activate brown adipose tissue in humans
    Maarten J. Vosselman · 2015
  62. EXPLORING BETA 3 ADRENOCEPTORS FOR POTENTIAL CLINICAL APPLICATIONS. Review Article
    Arunima Sen, Vikram Narayan Nichani · 2010
  63. Pericardial fat is a nutritionally regulated depot of brown adipose tissue
    Shalini Ojha · 2015 · Nottingham ePrints (University of Nottingham)
  64. Genetics of Cardiovascular Risk in Obesity
    Piers R. Blackett, Dharambir K. Sanghera · 2015 · Springer eBooks
  65. Brown fat as a therapy for obesity and diabetes
    Roy Jesse Shephard · 2011 · Yearbook of Sports Medicine
  66. Distinct Genetic Backgrounds in Quantitative Traits Preceding Type 2 Diabetes: One Reason for Missing Heritability
    Piers R. Blackett, Dharambir K. Sanghera · 2013 · Journal of Advances in Medicine and Medical Research
  67. Recent Developments in Diabetes Therapy
    Saikat Sen, Raja Chakraborty, Biplab De · 2016 · Springer eBooks
  68. Adipose Drug Targets for Obesity Treatment
    Jean‐Paul Giacobino, Lorenz Lehr, Olivier Boss · 2007 · CRC Press eBooks
  69. Brown Adipose Tissue as a Therapeutic Target
    Wouter D. van Marken Lichtenbelt, Emmani B. M. Nascimento · 2017 · Springer eBooks
  70. Pathophysiology of Obesity and Cancer: Drugs and Signaling Targets
    Ahood Khalid, Hira Khalid, Neelam Faiza, Anees Ahmed Khalil, Kiran Shahbaz, Ayesha Aslam, Quratul Ain Shahid, Surajudeen Abiola Abdulrahman, Chukwuebuka Egbuna, Kingsley Chukwuemeka Patrick-Iwuanyanwu · 2021 · Springer eBooks
  71. I Can Get Fat Where? The Other Types of Fat
    Nathan Denton · 2021 · Oxford University Press eBooks
  72. Review of Al-Qaeda's Armies: Middle East Affiliate Groups and the Next Generation of Terror
    Avi Jorisch · 2005 · Middle East Quarterly
  73. Obesity
    2006 · Wiley Handbook of Current and Emerging Drug Therapies
  74. Genetics of Cardiovascular Risk in Obesity
    Piers R. Blackett, Dharambir K. Sanghera · 2016 · Springer eBooks
  75. References
    2011 · CRC Press eBooks
  76. Βeta 3 Adrenoseptörlerin Hikayesi ve Etkileri
    Ayper Boğa Pekmezekmek · 2022 · Arşiv Kaynak Tarama Dergisi
  77. Phytocompounds That Target White Adipose Tissue for Weight Loss: A Review Spanning From Ucp1 Induction in Rodents to Human Clinical Trials
    Ann A. Coulter, Frank L. Greenway, Guru Ramanathan, Jacqueline R. Hubbard, Candida Joan Rebello · 2026 · Obesity Reviews
  78. BindingDB Entry 50039497: Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity.
    BindingDB · 2013 · UC San Diego
  79. BindingDB Entry 50033051: Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective humanß3 adrenergic receptor agonists.
    BindingDB · 2011 · UC San Diego
  80. BindingDB Entry 50047058: Discovery of Vibegron: A Potent and Selectiveß3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.
    BindingDB · 2017 · UC San Diego
  81. BindingDB Entry 50044030: Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
    BindingDB · 2014 · UC San Diego
  82. BindingDB Entry 50035396: Potent and selective, sulfamide-based human beta 3-adrenergic receptor agonists.
    BindingDB · 2012 · UC San Diego
  83. BindingDB Entry 50018277: Potent benzimidazolone based human beta(3)-adrenergic receptor agonists.
    BindingDB · 2009 · UC San Diego
  84. BindingDB Entry 50021381: Potent oxindole based human beta3 adrenergic receptor agonists.
    BindingDB · 2009 · UC San Diego